Protocolo de asistencia clínica en la psicosis

  1. Álvarez-Mon, Miguel Ángel 1
  2. Vidal, C. 1
  3. Ortuño, Felipe 1
  1. 1 Departamento de Psiquiatría y Psicología Médica. Clínica Universidad de Navarra, Pamplona. Navarra, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2019

Título del ejemplar: Enfermedades psiquiátricas (III) Psicosis. Trastornos del humor

Serie: 12

Número: 86

Páginas: 5075-5080

Tipo: Artículo

DOI: 10.1016/J.MED.2019.09.016 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Although antipsychotic drugs are effective against positive psychosis symptoms, their effectiveness is limited against negative ones. Treatment has to be supplemented with non-pharmacological measures (psychoeducation, cognitive rehabilitation, social skills training). One of the greatest challenges is therapeutic adherence, being crucial to achieve a good evolution. The best therapeutic option for treatment-resistant schizophrenia is clozapine.

Referencias bibliográficas

  • Bioque M, García-Portilla MAP, García-Rizo C, Cabrera B, Lobo A, González-Pinto A. Evolution of metabolic risk factors over a two year period in a cohort of first episodes of psychosis. Schizophr Res [Internet]. 2018;193:188-96.
  • Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA. Cardiometabolic risk in patients with first episode schizophrenia spectrum disorders. JAMA Psychiatry. 2014 Dec;71(12):1350
  • Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-30.
  • Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-71.
  • McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry [Internet]. 2003;183:534-9.
  • Mitchell AJ, Vancampfort D, De Hert M, Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry [Inter-net]. 2015;37(1):14-23.
  • Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL, Duque-González B. The costs of schizophrenia in Spain. Eur J Heal Econ. 2006;7(3):179-84.
  • Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86-97.
  • Westman J, Eriksson SV, Gissler M, Hällgren J, Prieto ML, Bobo WV. Increased cardiovascular mortality in people with schizophrenia: a 24 year national register study. Epidemiol Psychiatr Sci. 2018;27(5):519-27.
  • Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-85.
Fuente de los datos: Dialnet